VNRX insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Reynolds Cameron John President and CEO · Director · VOLITIONRX LTD | VNRX VOLITIONRX LTD | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 185781 · SEC code covers open-market or private transactions · On April 28, 2026, the Issuer effected a one-for-20 reverse stock split of its issued and outstanding common stock and made proportionate retroactive adjustments to its outstanding equity awards to the extent required including with respect to then-outstanding RSUs (the "Reverse Split"). No fractional shares were issued in connection with the Reverse Split, and each holder who otherwise would have been entitled to receive a fractional share received one whole share of common stock in lieu of such fractional share. Accordingly, the amount of securities beneficially owned directly and indirectly in column 5 of Table 1 has been adjusted to reflect the impact of the Reverse Split. | 2026-11-19 | 2026-11-20 | ≈ $6,848.00 40,000 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.